FogPharma Announces $178 Million Series D Financing to Advance Pipeline of First-in-Class Helicon Polypeptide Therapeutics Targeting Major Cancer Drivers
Read More
Posts by TizianiWhitmyre
Insider: A former Harvard chemist just raised $178 million for a biotech startup that plans to treat previously untreatable cancers
Read More
PharmaVOICE 100: WeiQing Zhou
Read More
FierceBiotech: Biopharma begins to hand AI the keys to the research car
Read More
FogPharma Announces Selection of Clinical Development Candidate Directly Targeting β-Catenin
Read More
FogPharma Expands Executive Leadership Team
Read More
Endpoints: Harvard’s Gregory Verdine has big ambitions for his miniprotein ‘braces’ — and now $107M to guide them to the clinic
Read More
FogPharma® Announces $107 Million Series C Financing to Advance Direct β-Catenin Antagonist and Universal Druggability™ Platform
Read More
Cambridge Discovery Park Building 400-500 Will be New Headquarters for FogPharma and LifeMine Therapeutics
Read More
FogPharma Appoints Dr. Barbara Weber to its Board of Directors
Read More